• 5분 읽기
• 2025년 9월 16일 게시
안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
Let’s be honest, shall we? The investment world can feel like a particularly frantic casino at times. One minute, everyone is piling into some tech firm that promises to revolutionise how we order a takeaway, and the next, it’s all gone pear-shaped. It’s exhausting. Amidst this chaos, I find myself increasingly drawn to the quiet, dependable, and dare I say, slightly boring world of healthcare. Because while trends come and go, one thing is stubbornly certain. People will always get ill, and they will always get old.
This isn't a sector built on hype. It’s built on the fundamental, non-negotiable realities of human life. You don’t cancel a prescription because the stock market had a bad day, nor do you postpone a hip replacement because of inflation figures. This inelastic demand is what gives the sector its backbone. It’s the sensible adult in a room full of excitable teenagers.
And the tailwinds here are not fleeting. We are living in an ageing world. The World Health Organisation isn't shy about projecting that healthcare spending will outpace GDP growth in most developed nations. This isn’t a speculative punt on a new technology. It’s a demographic certainty, a slow-moving but powerful current that could lift the entire sector for decades to come. The question for an investor, then, is not if this is a solid theme, but how to get a piece of it.
When you look at the big players, Johnson & Johnson often comes to mind first, and for good reason. To me, it’s less a single company and more a sprawling healthcare empire. It doesn’t just make blockbuster drugs. It also makes the surgical tools in the operating theatre and the plasters in your bathroom cabinet. This diversification is its superpower. When one area faces a headwind, like a patent expiring on a key drug, the other divisions are there to provide ballast.
This structure has allowed it to become what the Americans call a ‘Dividend Aristocrat’, which is a fancy way of saying it has reliably paid and increased its dividend for over half a century. In a world of fleeting promises, that sort of track record speaks volumes. It suggests a business built on foundations of stone, not sand. To me, this makes Johnson & Johnson (Healthcare Diversification) a fascinating case study in corporate resilience.
Of course, J&J isn't the only game in town. You also have the focused powerhouses like Pfizer and Merck. Pfizer, fresh from its starring role in the pandemic, is now sitting on a mountain of cash, which it can plough into research for the next big breakthrough. It’s a bet on pure innovation. Merck, on the other hand, shows the power of dominating a niche. Its cancer drug, Keytruda, has been a phenomenal success, demonstrating how getting one thing spectacularly right can drive immense value. These companies offer a different flavour, a more concentrated wager on scientific discovery.
Now, I wouldn't want you to think this is a risk-free ride. Nothing is. The path from a laboratory to a pharmacy is long, expensive, and littered with failures. Patents, the very things that protect a blockbuster drug’s profits, eventually expire, opening the door to a flood of cheaper generics. And let’s not forget the politicians, who love nothing more than to make noise about drug pricing. These are real risks that can, and do, affect share prices. Any sensible investor needs to go in with their eyes wide open. But for those seeking a degree of stability in their portfolio, the long-term case for healthcare remains, in my view, remarkably compelling.
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
전체 바스켓 보기:Johnson & Johnson (Healthcare Diversification)
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 18일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 18일 게시
기사 읽기